Triazolam Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.125 mg, 0.25 mg
Reference Brands: Halcion (USA)
Category:
Neurology
Triazolam is available in Tablets
and strengths such as 0.125 mg, 0.25 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Triazolam is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Triazolam can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Triazolam is a short-acting central nervous system (CNS) depressant belonging to the triazolobenzodiazepine class, a subgroup of benzodiazepine derivatives. It is widely recognized for its potent sedative and hypnotic effects and is primarily used in the short-term treatment of severe and acute insomnia. Triazolam is marketed under the brand name Halcion and other approved generic formulations in regulated markets.
Pharmacologically, triazolam enhances the inhibitory action of gamma-aminobutyric acid (GABA) in the brain, resulting in pronounced sedative, anxiolytic, amnesic, anticonvulsant, and muscle-relaxant properties. Due to its rapid onset of action and short elimination half-life, triazolam is particularly effective in inducing sleep while minimizing residual morning drowsiness. Its effects typically promote sleep for a limited duration, making it suitable for sleep-onset difficulties rather than sleep maintenance.
In addition to insomnia management, triazolam is sometimes used as an adjunct in medical and dental procedures requiring sedation, as well as to reduce anxiety during short diagnostic procedures such as MRI scans. Triazolam was first patented in 1970 and approved for use in the United States in 1982, and it remains a commonly prescribed hypnotic when used under strict medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing